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The Brugada syndrome accounts for approximately 20% of
cases of sudden cardiac death in patients with structurally
normal hearts (1–3). The syndrome is characterized by an
ST-segment elevation in right precordial leads (V1 to V3)
unrelated to ischemia, electrolyte disturbances or obvious
structural heart disease, and is sometimes accompanied by a
right bundle branch block (RBBB) morphology of the QRS.
This electrocardiographic (ECG) signature was reported as
early as 1953, but it was first described as a distinct clinical
entity associated with a high risk of sudden cardiac death by
Pedro and Josep Brugada in 1992 (4). These characteristics
of the Brugada syndrome are similar to those reported by
Nademanee et al. (5) for patients with sudden unexplained
death syndrome, and recent study has advanced data sug-
gesting the two syndromes are genetically and functionally
the same disorder (6).
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The ECG sign of the Brugada syndrome is dynamic and
often concealed, but it can be readily unmasked by potent
sodium channel blockers, such as flecainide, ajmaline, pro-
cainamide and psilicainide (7). Although intravenous ad-
ministration of these agents is most effective in unmasking
the syndrome, oral formulations are useful as well. In
general, the effectiveness of sodium channel blockers to
unmask the syndrome is inversely proportional to the rate at
which the drug dissociates from the sodium channel (8).
Class IC antiarrhythmics (flecainide) dissociate from the
sodium channel more slowly, display the greatest use-
dependent block of the sodium channel and are most
effective in elevating the ST-segment in Brugada patients.
Class IA agents (disopyramide, procainamide) dissociate
more rapidly than class IC agents, display less use-
dependent block of INa and are less effective. Class IA agents
with actions to block the transient outward current (Ito) in
addition to INa (quinidine) may exert an opposite effect,
leading to normalization of the ST-segment. Finally, class
IB agents, which display little use-dependence owing to
rapid dissociation from the sodium channel, are not at all
effective in unmasking the Brugada syndrome.
Both the specificity of these effects of sodium channel
blockers to uncover the syndrome and the prognostic
significance of these effects are slowly coming into better
focus. Recent studies have shown that asymptomatic pa-
tients whose Brugada sign is only present after a sodium
challenge have a much better prognosis than those whose
ECG sign is present spontaneously (9).
The sensitivity to sodium channel block is consistent with
linkage of the syndrome to a defect in the sodium channel
gene. The only gene thus far linked is that encoding for the
alpha subunit of the cardiac sodium channel gene, SCN5A
(3,10–14), the same gene implicated in the LQT3 form of
the long QT syndrome and in progressive conduction
disease. Bezzina et al. (14) uncovered a mutation in SCN5A
(1795InsD) capable of producing both the Brugada and
LQT3 phenotypes, and Kyndt et al. (15) have recently
reported an SCN5A gene mutation capable of producing
both the Brugada syndrome and progressive conduction
disease. The SCN5A mutations linked to the Brugada
syndrome cause a reduction in the availability of INa second-
ary to either: 1) failure of the sodium channel to express, 2)
a shift in the voltage- and time-dependence of INa activation,
inactivation or reactivation, and/or 3) acceleration of the
inactivation of the sodium channel (3,11,12,14). Premature
inactivation of the sodium channel can be temperature
sensitive (11), providing a possible explanation for the effect
of fever to unmask the syndrome in some Brugada patients
(16).
Another locus on chromosome 3, close to but distinct
from SCN5A, has recently been linked to the syndrome
(17). The Brugada syndrome in this single large pedigree
was associated with progressive conduction disease, a low
sensitivity to procainamide, and a relatively good prognosis.
In addition to SCN5A, gene mutations that alter the
intensity or kinetics of Ito, IKr, IKs, IK-ATP, ICa, or ICl(Ca) so as
to increase the activity of the outward currents and/or
diminish that of the inward currents are candidates for the
Brugada syndrome. Other candidate genes include those
encoding for autonomic receptors that directly modulate ion
current density and/or alter the expression of channels in the
membrane (e.g., sympathetic control of Ito) (18,19).
Cellular mechanisms responsible for development of the
Brugada syndrome are also coming into better focus. Elec-
trocardiographic manifestations of the syndrome have been
attributed to one of two basic mechanisms: 1) conduction
delay in the right ventricular (RV) epicardial-free wall in the
region of the outflow tract, or 2) premature repolarization of
the RV epicardial action potential secondary to loss of the
action potential dome.
A schematic representation of the cellular changes be-
lieved to underlie the Brugada phenotype in hypothesis 2 is
shown in Figure 1 (18,20). In larger mammals, the presence
of an Ito-mediated spike and dome morphology, or notch, in
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ventricular epicardium, but not endocardium, creates a
transmural voltage gradient responsible for the inscription
of the ECG J-wave (21). Under normal conditions, the
J-wave is relatively small, in large part reflecting the left
ventricular action potential notch, as that of RV epicardium
is usually buried in the QRS complex. The ST-segment is
isoelectric because of the absence of transmural voltage
gradients at the level of the action potential plateau (Fig.
1A). Accentuation of the RV notch under pathophysiologic
conditions leads to exaggeration of transmural voltage gra-
dients and thus to accentuation of the J-wave or to J-point
elevation. This would be expected to give rise to a saddle-
back configuration of the repolarization waves (Fig. 1B).
The development of a prominent J-wave under these
conditions is indistinguishable from an ST-segment eleva-
tion. Under these conditions, the T-wave remains positive
because epicardial repolarization precedes repolarization of
the cells in the M and endocardial regions. Further accen-
tuation of the notch may be accompanied by a prolongation
of the epicardial action potential such that the direction of
repolarization across the RV wall and transmural voltage
gradients are reversed, leading to the development of a
coved-type ST-segment elevation and inversion of the
T-wave (Fig. 1C), typically observed in the ECG of
Brugada patients.
A delay in epicardial activation may also contribute to
inversion of the T-wave. The downsloping ST-segment
elevation, or accentuated J-wave, observed in the experi-
mental wedge models often appears as an R, suggesting
that the appearance of an RBBB morphology in Brugada
patients may be due at least in part to early repolarization of
RV epicardium, rather to impulse conduction block in the
right bundle. Indeed, a rigorous application of RBBB
criteria reveals that a large majority of RBBB-like morphol-
ogies encountered in cases of Brugada syndrome do not fit
the criteria for RBBB (22). Moreover, attempts by Miyazaki
et al. (23) to record delayed activation of the right ventricle
in Brugada patients met with failure. Although the typical
Brugada morphology is present in Figures 1B and 1C, the
substrate for re-entry is not. We believe that the arrhyth-
mogenic substrate arises when a further shift in the balance
of current leads to loss of the action potential dome at some
epicardial sites but not others (Fig. 1D). Loss of the action
potential dome in epicardium but not endocardium results
in the development of a marked transmural dispersion of
repolarization and refractoriness, responsible for the devel-
Figure 1. Schematic representation of right ventricular epicardial action potential changes proposed to underlie the electrocardiographic (ECG)
manifestation of the Brugada syndrome. Modified from Antzelevitch (20), with permission.
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opment of a vulnerable window during which a premature
impulse or extrasystole can induce a re-entrant arrhythmia.
Loss of the action potential dome in epicardium is usually
heterogeneous, leading to the development of epicardial
dispersion of repolarization (Fig. 1D). Conduction of the
action potential dome from sites at which it is maintained to
sites at which it is lost causes local re-excitation via a phase
2 re-entry mechanism, leading to the development of a very
closely coupled extrasystole, which captures the vulnerable
window across the wall, thus triggering a circus movement
re-entry in the form of ventricular tachycardia (VT)/
ventricular fibrillation (VF) (Fig. 1E) (24,25). The phase 2
re-entrant beat fuses with the negative T-wave of the basic
response. Because the extrasystole originates in epicardium,
the QRS complex is largely comprised of a Q-wave, which
serves to accentuate the negative deflection of the inverted
T-wave, giving the ECG a more symmetrical appearance.
This morphology is often observed in the clinic preceding
the onset of polymorphic VT. Support for these hypotheses
derives from experiments involving the arterially perfused
RV wedge preparation (25).
These characteristics of ventricular epicardium suggest
that activation forces, generated by the second upstroke of
the RV epicardial action potential and/or phase 2 re-entry,
may extend beyond the QRS complex in Brugada patients.
Indeed, signal-averaged ECG (SAECG) recordings have
demonstrated late potentials in patients with the Brugada
syndrome, especially in the anterior wall of the RV outflow
tract (RVOT) (26,27). The basis for these late potentials,
commonly ascribed to delayed conduction within the ven-
tricle, are largely unknown. Endocardial recordings have
been unrevealing. A study by Nagase et al. (28), reported in
this issue of the Journal, sheds some light on this subject.
The investigators introduced a guide wire into the conus
branch of the right coronary artery to record signals from
the epicardial surface of the anterior wall of the RVOT in
patients with the Brugada syndrome. This novel approach
yielded unipolar recordings displaying delayed potentials,
which coincide with late potentials recorded in the
SAECG. The study demonstrates extension of the delayed
unipolar potentials and ECG late potentials further into
diastole following the administration of class IC antiar-
rhythmic agents. The investigators conclude that recordings
from the conus branch of the right coronary artery can
identify an “epicardial abnormality” in the RVOT, which is
accentuated in the presence of class IC agents, thus uncov-
ering part of the arrhythmogenic substrate responsible for
VT/VF in Brugada syndrome.
This brief communication elegantly describes a study
novel in its approach, which may be useful in the further
delineation of the mechanisms underlying arrhythmogenic-
ity in the Brugada syndrome. The researchers are prudently
cautious in drawing any conclusions. Whereas late poten-
tials are commonly regarded as being representative of
delayed activation of the myocardium, in the case of the
Brugada syndrome other possibilities exist as previously
discussed. For example, the second upstroke of the epicar-
dial action potential, thought to be greatly accentuated in
Brugada syndrome (29), might be capable of generating late
potentials when RVOT activation is otherwise normal.
Moreover, the occurrence of phase 2 re-entry, especially
when concealed (i.e., when it fails to trigger transmural
re-entry), may contribute to the generation of delayed
unipolar and late SAECG potentials. One concern regard-
ing the approach used by Nagase et al. (28) is that the conus
artery recordings may represent a composite of local events
as well as activity from remote sites extending to the left
ventricular cavity to which the conus artery is attached
through the low resistivity of the blood. The investigators
address this issue by pointing out that the delayed potentials
do not correspond to potentials recorded from the left
ventricular endocardium. Thus, the study by Nagase et al.
(28) supports both hypotheses advanced to explain the ECG
manifestation of the Brugada syndrome.
How then can we discriminate between the two? One
approach is to examine the rate-dependence of the ECG
sign. If the Brugada ECG sign is due to delayed conduction
in the RVOT, acceleration of the rate would be expected to
further aggravate conduction and thus accentuate the ST-
segment elevation and the RBBB morphology of the ECG.
Conversely, if the Brugada sign is secondary to accentuation
of the epicardial action potential notch, at some point
leading to loss of the action potential dome, acceleration of
the rate would be expected to normalize the ECG, by
restoring the action potential dome and reducing the notch.
This occurs because the transient outward current, which is
at the heart of this mechanism, is slow to recover from
inactivation and is less available at faster rates. The fact of
the matter is that Brugada patients usually display a nor-
malization of their ECG or no change when heart rate is
increased, thus favoring the second hypothesis (Fig. 1).
Further evidence in support of this hypothesis derives from
the recent observations of Shimizu et al. (30). Using a
unipolar catheter introduced into the great cardiac vein, they
recorded unipolar activation recovery intervals (ARIs), a
measure of local action potential duration, from the epicar-
dial surface of the RVOT in a 53-year-old Brugada patient.
The ARIs in the RVOT were observed to abbreviate
dramatically whenever the ST-segment was elevated in lead
V2 following a pause or the administration of a sodium
channel blocker. Thus, the available data, both experimental
and clinical, point to transmural voltage gradients that
develop secondary to accentuation of the epicardial notch
and loss of the action potential dome as being in large part
responsible for the Brugada ECG signature.
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